Drug Profile
Research programme: MKC 1106 immunotherapies - Colby Pharmaceutical/MannKind Corporation
Alternative Names: MKC 1106-NS; MKC1106 active immunotherapiesLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MannKind Corporation
- Developer Colby Pharmaceuticals; MannKind Corporation
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Intralymphatic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intralymphatic, Injection)
- 13 Nov 2012 MKC 1106 immunotherapy programme licensed to Colby Pharmaceutical Company worldwide